J&J's RNAi suppresses hepatitis B for 48 weeks after last dose

Johnson & Johnson has presented clinical trial data linking short-term treatment with RNAi therapy JNJ-3989 to sustained reductions in markers of hepatitis B infection. The data drop comes as J&J runs 48-week phase 2b trials of the Arrowhead-partnered drug in the pursuit of a functional cure.